As such, a rational approach to validate the TICs of ccRCC may be to inactivate VHL specifically in one of these RSPCs, and examine the tumor-initiating property of the resultant mutant progenitor cells. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.